ANTICUERPOS ANTI-STEAP2, CONJUGADOS ANTICUERPO-FARMACO, Y MOLECULAS DE FIJACION AL ANTIGENO BIESPECIFICAS QUE SE FIJAN A STEAP2 Y CD3, Y USOS DE ESTOS.
Eric SMITH,Thomas NITTOLI,Frank DELFINO,Jessica R. KIRSHNER,Lauric HABER,John RUDGE,Alison CRAWFORD
申请号：
MX2019003325
公开号：
MX2019003325A
申请日:
2017.09.22
申请国别(地区):
MX
年份:
2019
代理人:
摘要：
The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2 -expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2 -targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.La proteína conocida como antígeno epitelial de seis transmembranas de próstata 2 (STEAP2) se expresa altamente en el cáncer de próstata y está asociada con la expresión de otros genes asociados con el cáncer de próstata. La presente invención proporciona anticuerpos contra IgG humana de longitud completa novedosos que se fijan a STEAP2 humano (anticuerpos monoespecíficos). La presente invención también proporciona anticuerpos biespecíficos (bsAbs) novedosos que se fijan a STEAP2 y CD3 y activan tos linfocitos T a través del complejo CD3 en presencia de tumores
